Tivantinib

N/A

Report date: 2024/01/14 20:01:44
NME

Base Information

Drug NameTivantinib
Drug Alias NameTivantinibum替万替尼ARQ-197
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsSolid tumoursLiver Cirrhosis +[22] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArqule Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKyowa Kirin Co LtdArqule IncNational Cancer Institute +[5] 
Active IndicationsN/A
Inactive IndicationsHormone-Resistant Prostate NeoplasmsSolid tumoursLiver Cirrhosis +[22] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG